Navigation Links
Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
Date:5/5/2009

mated 49,960 deaths (American Cancer Society, Cancer Facts and Figures 2009). The current standard of care is associated with significant side effects including neuropathy, which can limit its use and result in its discontinuation. Effective first-line, neuropathy sparing treatment for CRC is a major unmet medical need.

About Prostate Cancer

More than 1 million American men are currently living with prostate cancer and it is the second leading cause of death among men in the U.S. In 2008, an estimated 186,320 new cases of prostate cancer were expected to be diagnosed in the U.S., with an estimated 28,660 deaths (American Cancer Society, Cancer Facts and Figures 2009). CRPC is prostate cancer that continues to grow despite current standard of care hormonal (anti-androgen) therapies. CRPC is more invasive and more likely to spread to other organs than androgen dependent prostate cancers. Patients with CRPC have few treatment options and a poor prognosis.

About Picoplatin

Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that it has an improved safety profile relative to existing platinum-based cancer therapies. More than 1,100 patients have received picoplatin. Results obtained to date suggest manageable hematologic adverse events with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs. Picoplatin has demonstrated anti-tumor activity in a variety of solid tumors. It is being studied in multiple cancer indications, treatment combinations and by two routes of administration.

Conference Call Details

Poniard's management team will host a live conference call and Webcast today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. To participate by telephone, please di
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Israel , June 19, 2013 ... a phase I study in volunteers, and preliminary results ... of ND0612, were presented at the 2013 International Congress ... proprietary levodopa/carbidopa liquid drug formula under development for continuous ... maintain constant levodopa plasma concentrations. ND0612 has ...
(Date:6/19/2013)...   Life Technologies Corporation (NASDAQ: ... Suzhou Ribo Life Sciences (Ribo) the exclusive rights ... China using Life,s Invivofectamine® Rx ... in combination with Invivofectamine® Rx to create a ... high unmet medical need in the Chinese healthcare ...
(Date:6/19/2013)... Juni 2013 Specialty Coating ... Entwicklung von SCS microRESIST™, einer antimikrobiellen ... Beschichtung mit Parylene gelungen ist. SCS ... Parylene mit antimikrobiellen Eigenschaften und erlaubt ... auf beschichteten medizinischen Geräten. ...
Breaking Medicine Technology:NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2
... TARRYTOWN, N.Y. and BERLIN, April 8, 2011 ... and Bayer HealthCare today announced that they have initiated ... the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic ... certain eye diseases, in the treatment of Diabetic Macular ...
... Texas, April 7, 2011 Assured Pharmacy (APHY: pinksheets), ... more than 3,000 sufferers of chronic pain, has filed ... to effect a 1-for-180 reverse stock split of the ... reverse stock split in the number of issued and ...
Cached Medicine Technology:Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 2Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 3Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 4Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 5Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 6Assured Pharmacy Announces Reverse Stock Split 2Assured Pharmacy Announces Reverse Stock Split 3
(Date:6/19/2013)... CCA , America's leader in partnership corrections, ... President, Health Services, effective June 8, 2013. Dr. ... CCA. He will replace the retiring Herb Spiwak. ... lead CCA's dedicated team of health care professionals. ... our partners as we provide effective care to persons ...
(Date:6/19/2013)... Chrysler made news recently when it refused ... million Jeeps. The Jeep models in question are the 1993-2004 ... to the NHTSA are vulnerable to fire and explosion in ... are rear-mounted and have been alleged to catch fire or ... Cherokee with 32 rear-end crashes, which resulted in 44 deaths ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 According to a ... Surviving Weekend Sunburn,” it is not uncommon for a person ... summer months. A person is likely to forget to reapply ... which is both dry and itchy. When this occurs, it ... to goo.gl/gDyjP). , “Most people do not realize that milk ...
(Date:6/19/2013)... online edition of the journal Nature , a ... California, San Diego School of Medicine visually monitored the ... occurs in zebrafish after cardiac ventricular injury. Their ... heart are more plastic, or capable of transformation into ... the research reveals a novel potential source of cells ...
(Date:6/19/2013)... Spanish . ... goes by the name of the 10/90 gap: only 10 ... that accounted for 90 per cent of the global disease ... for Neglected Diseases initiative (DNDi) came into being in 2003. ... granted the BBVA Foundation Frontiers of Knowledge Award in the ...
Breaking Medicine News(10 mins):Health News:CCA Names Dr. John Baxter Vice President, Health Services 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 3Health News:Skin Care – How to treat Sunburn 2Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5
... French . , Montreal, March 11, 2009 ... influence of cannabis (DUIC) and engage in reckless driving, according ... the journal Accident Analysis and Prevention , men who ... consider taking the wheel after consuming cannabis more often than ...
... 11 On Friday, March 6, 2009, Coast ... Justice, the FBI, the FDA, and the Commonwealth of Virginia ... Independent Review Board discovered that a protocol submitted for review ... of Clifton, Virginia, was fraudulent in violation of federal and ...
... most progressive benefit management firms, today announced a strategic partnership with ... will enable CBCA to provide an unparalleled suite of proven care ... ... OH (Vocus) March 11, 2009 -- CBCA Administrators, Inc. (CBCA), one ...
... LOS ANGELES, March 11 MMR Information ... through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ... Records ("PHRs") ( www.mymedicalrecords.com ) and electronic ... ), announced that it has selected Gene ...
... March 11 The U.S. Agency for ... in Southern Africa launched a new program to reduce ... and Mpumalanga Provinces. The three-year, $5.1 million project is ... Relief (PEPFAR), and administered by USAID . A ...
... researchers wanted to know whether an increased CO2 ... therefore examined freshwater micro-algae: small, floating and mostly ... tanks called limnotrons. These were aerated with ordinary ... of CO2. The researchers then examined the ratio ...
Cached Medicine News:Health News:Study finds cannabis use, dangerous driving behaviors interrelated 2Health News:Clinical Trial Fraud Exposed by Coast IRB 2Health News:CBCA Administrators, Inc. Announces Strategic Partnership with KePRO 2Health News:CBCA Administrators, Inc. Announces Strategic Partnership with KePRO 3Health News:MMR Information Systems, Inc. Taps Health Information Technology Veteran Gene Barduson 2Health News:MMR Information Systems, Inc. Taps Health Information Technology Veteran Gene Barduson 3Health News:MMR Information Systems, Inc. Taps Health Information Technology Veteran Gene Barduson 4Health News:MMR Information Systems, Inc. Taps Health Information Technology Veteran Gene Barduson 5Health News:USAID and IOM Announce HIV Prevention and Care for Farm Workers 2
Each handle is designed to fit a specific trephine size....
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
... Ophthalmic Products are constructed of ... lint-free MEROCEL polyvinyl acetal sponge. ... be beneficial to both surgeon ... and yet firm enough to ...
Medicine Products: